Ruben J Trujillo, Sara Lok, Lawrence J Bonassar, David Putnam
{"title":"Controlled Release of the IL-1R Antagonist, Anakinra, from Microgels with an Extended Intra-articular Residence Time.","authors":"Ruben J Trujillo, Sara Lok, Lawrence J Bonassar, David Putnam","doi":"10.1007/s11095-026-04196-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To establish intra-articularly injected microgel compositions that can control the rate of release of anakinra, a protein-based IL-1R antagonist, at therapeutically relevant concentrations for an extended period of time.</p><p><strong>Methods: </strong>Uptake and release of the IL-1Ra from microgels was tuned by simple post-synthesis modifications via the addition of calcium chloride after protein loading, or conjugation of small molecules to existing microgels to study the effects of negative (unmodified), positive (dimethylethylenediamine, agmatine), polar (ethanolamine), and non-polar (phenethylamine) side chains on protein delivery.</p><p><strong>Results: </strong>Microgels modified with phenethylamine enhanced the loading capacity of the IL-1Ra to 242%. Both calcium-treated and small molecule-modified microgels had a decrease in initial burst release from the microgel matrix, and both extended the release of IL-1Ra from 6 h for unmodified microgels to over 60 days within the active therapeutic index of the drug. Microgels persist in the joint space for at least 8 weeks, and follow a bi-exponential decay curve with a ß half-life of 93.2 days.</p><p><strong>Conclusions: </strong>These findings demonstrate the application of simple post-synthesis modifications for improved drug delivery via polyanionic microgels, and support the potential use of poly(acrylic acid) microgels as intra-articular drug delivery vehicles for osteoarthritis treatment.</p>","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"2967-2988"},"PeriodicalIF":4.1000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13642450/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11095-026-04196-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To establish intra-articularly injected microgel compositions that can control the rate of release of anakinra, a protein-based IL-1R antagonist, at therapeutically relevant concentrations for an extended period of time.
Methods: Uptake and release of the IL-1Ra from microgels was tuned by simple post-synthesis modifications via the addition of calcium chloride after protein loading, or conjugation of small molecules to existing microgels to study the effects of negative (unmodified), positive (dimethylethylenediamine, agmatine), polar (ethanolamine), and non-polar (phenethylamine) side chains on protein delivery.
Results: Microgels modified with phenethylamine enhanced the loading capacity of the IL-1Ra to 242%. Both calcium-treated and small molecule-modified microgels had a decrease in initial burst release from the microgel matrix, and both extended the release of IL-1Ra from 6 h for unmodified microgels to over 60 days within the active therapeutic index of the drug. Microgels persist in the joint space for at least 8 weeks, and follow a bi-exponential decay curve with a ß half-life of 93.2 days.
Conclusions: These findings demonstrate the application of simple post-synthesis modifications for improved drug delivery via polyanionic microgels, and support the potential use of poly(acrylic acid) microgels as intra-articular drug delivery vehicles for osteoarthritis treatment.
期刊介绍:
Pharmaceutical Research, an official journal of the American Association of Pharmaceutical Scientists, is committed to publishing novel research that is mechanism-based, hypothesis-driven and addresses significant issues in drug discovery, development and regulation. Current areas of interest include, but are not limited to:
-(pre)formulation engineering and processing-
computational biopharmaceutics-
drug delivery and targeting-
molecular biopharmaceutics and drug disposition (including cellular and molecular pharmacology)-
pharmacokinetics, pharmacodynamics and pharmacogenetics.
Research may involve nonclinical and clinical studies, and utilize both in vitro and in vivo approaches. Studies on small drug molecules, pharmaceutical solid materials (including biomaterials, polymers and nanoparticles) biotechnology products (including genes, peptides, proteins and vaccines), and genetically engineered cells are welcome.